Altan Pharma Limited (“Altan”), an Irish specialty pharmaceutical company today announced that it has launched linezolid 2mg/ml solution for infusion for the treatment of community acquired pneumonia and nosocomial pneumonia in Spain through its Spanish subsidiary Genéricos Españoles Laboratorio, S.A.U.
According to IMS, the market for Linezolid solution for infusion in Spain was roughly €23 million in 2015.
ABOUT LINEZOLID SOLUTION FOR INFUSION
Linezolid is indicated for the treatment of community acquired pneumonia and nosocomial pneumonia when known or suspected to be caused by susceptible gram positive bacteria. It is also indicated for the treatment of complicated skin and soft tissue infections only when microbiological testing has established that the infection is known to be caused by susceptible Gram positive bacteria. Linezolid should only be initiated in a hospital setting.
Please see the package insert for indications, complete side effect profile and prescribing information.
Altan Media Relations
Tel: +353 (1) 908 1280